|
|
|
| Expression and Clinical Significance of VEGFp-Akt and PTEN in Non-small Cell Lung Cancer |
| ZHANG Xiuyi, XU Haoran, JING Weige, et al |
| The Central Hospital of Chengde, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To detect the expression of PTEN, p-Akt and VEGF protein in tissue of non small-cell lung cancer group and normal control groups, and discuss the mechanism of these three proteins in the pathogenesis of non-small cell lung cancer. Methods: 82 cases of tissue samples with non small-cell lung cancer and fifty eight cases of tissue samples from alveolus health control, and fifty six cases of tissue samples from bronchus health control were collected. The expression levels of them was measured by immunohistochemistry method and analyzed the relationship with the clinical and pathological data. Results: The expression of p-Akt and VEGF protein in lung cancer group, squamous cell carcinoma of the lung group and lung adenocarcinoma group was significantly higher than which in double normal control groups(P<0.01).p-Akt and VEGF expression in lung tissue were positively correlated. The expression levels of p-Akt protein were related to tumor size, differentiation degree, clinical stage and lymph node metastasis. The expression levels of VEGF protein were related to differentiation degree , clinical stage and lymph node metastasis. The expression levels of PTEN protein in lung cancer group, squamous cell carcinoma of the lung group and lung adenocarcinoma group is significantly lower than which in double normal control groups(P<0.01). The expression levels of PTEN protein were related to differentiation degree, clinical stage and lymph node metastasis. PTEN is negatively correlated with p-Akt and VEGF in tumor tissues. Conclusion: P-Akt and vascular endothelial growth factor play a synergistic role in the occurrence, invasion and metastasis of non-small cell lung cancer, and PTEN plays an inhibitory role.
|
|
|
|
|
|
[1] Yuichi Hisamatsu,Eiji Oki,Hajime Otsu,et al. Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer[J]. Ann Surg Oncol,2016,23(6):1986~1992.
[2] Frezzetti D,Gallo M,Maiello MR,et al. VEGF as a potential target in lung cancer[J]. Expert Opin Ther Targets,2017,21(10):959~966.
[3] Wang J,Xu-Monette ZY,Jabbar KJ,et al. Role of AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma[J]. Am Pathol,2017,187(8):1700~1716.
[4] Lixia Zhou,Yueming Wu,Yang Guo,et al. Calycosin enhances some chemotherapeutic drugs inhibition of Akt signaling pathway in gastric cells[J]. Cancer Investigation,2017,35(5):289~300.
[5] Frezzetti D,Gallo M,Maiello MR,et al. VEGF as a potential target in lung cancer[J]. Expert Opin Ther Targets,2017,21(10):959~966.
[6] Anna Shchayuk,Evelina Krupnova,Michael Shapetska,et al. Association between VEGF gene functional polymorphisms and clinical and pathological characteristics of non-small cell lung cancer: topic: biology[J]. Journal of Thoracic Oncology,2017,12(1):846~847.
[7] Malaney Prerna,Uversky Vladimir,Davé Vrushank. PTEN proteoforms inbiology and disease[J]. Cellular & Molecular Life Sciences,2017,74(15):2783~2794.
[8] Slomiany MG,Black LA,Kibbey MM,et a1.IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma[J]. Biochem Biophys Res Commun,2006,342(3):851~855.
[9] Zhang J,Song H,Lu Y,et al. Effects of estradiol on VEGF and bFGF by Akt in endometrial cancer cells are mediated through the NF-κB pathway[J]. Oncol Rep,2016,36(2):705~714.
[10] Moradzadeh M,Hosseini A,Erfanian S,et a1. Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase[J]. Pharmacol Rep,2017,69(5):924~928. |
|
|
|
2019, Vol. 25 
